Yisheng Biopharma Co Ltd, a biopharmaceutical company, has received a Pharmaceutical GMP Certificate from the China National Medical Products Administration (NMPA) for production of its Yisheng Junan product, the first lyophilised rabies vaccine without an aluminium adjuvant produced in China for medical use, it was reported yesterday.
The vaccine has demonstrated effective protection, contributing to the fight against rabies infection. The newly constructed state-of-art production facility is operated by the Liaoning Yisheng Biopharma subsidiary.
Zhang Yi, chairman of Yisheng Biopharma, said, 'As a vaccine manufacturer with a history dating back to 1994, Yisheng was the first private biopharmaceutical company to benefit from the dynamic evolution of vaccine technology in China and has long been a leader in technology innovation in rabies vaccine production. Now, we have invested approximately USD60m to build two new vaccine production facilities and successfully completed the GMP certification process.'
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine